$DRI

DRI Maintained by Morgan Stanley -- Price Target Raised to $255

Morgan Stanley maintained an Overweight rating on Darden Restaurants (DRI) and raised its price target to $255 from $236, citing growth potential. DRI is currently trading at $214.43, slightly above its GF Value™ of $211.57, indicating a 1.4% overvaluation. The company has a GF Score™ of 85, reflecting strong financial health and profitability.

Original reporting
Published Sep 14, 2026, 4:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 6:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$DRI
Bullish
medium confidence
Mentioned
$DRI
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$DRIBullishMed
01

Why it matters

Analyst target raise may attract new buying interest, but insider sell activity could dampen enthusiasm.

02

Market read

The rating change offers a modest trading signal for DRI and may influence peer sentiment.

03

What to watch

Potential slowdown in discretionary spending could pressure restaurant earnings.

Relevance 6/10Novelty 5/10Timing: today

Background

Morgan Stanley maintains Overweight on Darden Restaurants and lifts its price target.

Company-level read

Ticker impact

$DRIBullishMedium confidence
Context

Morgan Stanley raised Darden Restaurants' price target to $255, up from $236.

Expected impact

Potential modest price gain as investors adjust expectations.

Evidence & confidence

Target raise signals improved outlook; however, insider selling and slight overvaluation temper the move.

Market effects

May lift sentiment for consumer‑cyclical restaurant peers.

Limited to U.S. equity markets.

Low

Counterpoint

Insider selling and a modest overvaluation suggest caution despite the target raise.

Key entities

  • Morgan Stanley

    Equity research firm providing the rating and target.

  • Darden Restaurants

    Operator of Olive Garden, LongHorn Steakhouse, etc.

Related articles

$CMGMed

Baird Reshuffles Restaurant Ratings: Starbucks, Cava Top Picks as Chipotle, Domino's Cut to Neutral — BigGo Finance

Baird downgraded Chipotle (CMG) to Neutral, cutting its price target to $40, citing slower growth and higher reinvestment needs. Domino's (DPZ) and Black Rock Coffee Bar (BRCB) were also downgraded. Darden (DRI) was upgraded to Outperform with a $250 target. Baird favors Cava (CAVA), Starbucks (SBUX), and others with strong unit economics and growth potential.

$CMGMed

Baird downgrades Chipotle, Domino’s as restaurant divergence widens

Baird downgraded Chipotle (CMG), Domino's (DPZ), and Black Rock Coffee Bar (BRCB) to Neutral, citing slower growth and competitive pressures. It upgraded Darden (DRI) to Outperform, praising its strong fundamentals. Price targets were adjusted for each. Baird also initiated coverage of Brinker (EAT) and Jersey Mike's with Outperform ratings, and named Cava (CAVA), Brinker, Starbucks (SBUX), and Dutch Bros (BROS) as top picks.

$DRIHighAI 8/10

Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?

Darden Restaurants (DRI) reached a 52-week high in 2026, with fiscal sales surpassing $13 billion. Key brands like Olive Garden and LongHorn Steakhouse drove growth, with Q4 revenue up 13.7% YoY. Darden's stock rose 18% this year, supported by strong earnings and a new $1.5 billion share repurchase plan. The company provided optimistic 2027 guidance, including sales between $13.6B and $13.75B. Competitors like Domino's (DPZ) and Chipotle (CMG) faced weaker sales and stock declines.

$DRIMed

DRI Healthcare Announces Receipt of Put Price on EKTERLY

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) said it received about US$178 million as the put price after exercising a contractual put option tied to its royalty participation right in EKTERLY. The put was exercised after Chiesi Group completed its acquisition of KalVista Pharmaceuticals. The transaction is now complete and the royalty right has terminated.